People
ADC Therapeutics SA, a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent antibody drug conjugates for patients suffering from hematological malignancies and solid tumors, announced the appointment of Victor Sandor, M.D., to its Board of Directors.
Recent reports revealed that the infection rates between adults and children were similar, but men are more likely to exhibit severe symptoms. The report also highlights the importance of contact tracing to help mitigate infection rates.
The study was run by Johns Hopkins University and Geisinger Health, testing more than 10,000 women with no previous history of cancer.
Expectations that a vaccine against COVID-19 will be available within a year’s time are mixed, based on recent surveys conducted by BioSpace, as well as the analytics company GlobalData.
Writing in The Motley Fool, Billy Duberstein, the portfolio manager at Stone Oak Capital, pointed at these two treatment options as potential weapons against the pandemic.
Saniona appoints Rudolf Baumgartner, M.D., as Chief Medical Officer and Head of Clinical Development
Saniona, a clinical stage biopharmaceutical company focused on rare diseases, announced that it has appointed Rudolf Baumgartner, M.D., as Chief Medical Officer and Head of Clinical Development starting on May 1, 2020.
Here is a cross-section of some of the surveys about the COVID-19 pandemic over the last few weeks.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 27, 2020.
Nuritas, a biotech company that focuses on leveraging artificial intelligence (AI) to discover therapeutic peptides, is joining the fight by tasking their powerful AI platform to find peptides that can be used as therapeutics for COVID-19.
Following news of Mammoth Biosciences’ CRISPR diagnostic assay to detect SARS-CoV-2, the company talked at length with BioSpace about this new test and its ramifications.
PRESS RELEASES